ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000D27

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Identifieur interne : 000D27 ( PascalFrancis/Corpus ); précédent : 000D26; suivant : 000D28

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Auteurs : V. D. Doan ; R. Grondin ; ABDALLAH HADJ TAHAR ; L. Gregoire ; P. J. Bedard

Source :

Clinical neuropharmacology [ 0362-5664 ] ; 1999.

RBID : Pascal:99-0526518

Descripteurs français

Pascal (Inist)
- Antagoniste dopamine, Antagoniste, Agoniste, Récepteur dopaminergique D1, Stimulant dopaminergique, Récepteur dopaminergique, Comportement, Parkinson maladie, Apomorphine, Lévodopa, Association médicamenteuse, Animal, Singe, Long terme, Voie orale, Latence réponse, Durée action, Dose répétée, Activité biologique, SCH 23390, NNC 010112, Antiparkinsonien.

English descriptors

KwdEn :
- Agonist, Animal, Antagonist, Antiparkinson agent, Behavior, Biological activity, D1 Dopamine receptor, Dopamine agonist, Dopamine antagonist, Dopamine receptor, Drug combination, Duration of action, Levodopa, Long term, Monkey, Multiple dose, Oral administration, Parkinson disease, Response latency.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0362-5664`
A02	`01`			`@0 CLNEDB`
A03		`1`		`@0 Clin. neuropharmacol.`
A05				`@2 22`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Effect of the selective D₁ antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys`
A11	`01`	`1`		`@1 DOAN (V. D.)`
A11	`02`	`1`		`@1 GRONDIN (R.)`
A11	`03`	`1`		`@1 ABDALLAH HADJ TAHAR`
A11	`04`	`1`		`@1 GREGOIRE (L.)`
A11	`05`	`1`		`@1 BEDARD (P. J.)`
A14	`01`			`@1 Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University @2 Québec @3 CAN @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 281-287`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 16720 @5 354000087950320060`
A44				`@0 0000 @1 © 1999 INIST-CNRS. All rights reserved.`
A45				`@0 37 ref.`
A47	`01`	`1`		`@0 99-0526518`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Clinical neuropharmacology`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Antagoniste dopamine @5 01`
C03	`01`	`X`	`ENG`	`@0 Dopamine antagonist @5 01`
C03	`01`	`X`	`SPA`	`@0 Antagonista dopamina @5 01`
C03	`02`	`X`	`FRE`	`@0 Antagoniste @5 02`
C03	`02`	`X`	`ENG`	`@0 Antagonist @5 02`
C03	`02`	`X`	`SPA`	`@0 Antagonista @5 02`
C03	`03`	`X`	`FRE`	`@0 Agoniste @5 03`
C03	`03`	`X`	`ENG`	`@0 Agonist @5 03`
C03	`03`	`X`	`SPA`	`@0 Agonista @5 03`
C03	`04`	`X`	`FRE`	`@0 Récepteur dopaminergique D1 @5 04`
C03	`04`	`X`	`ENG`	`@0 D1 Dopamine receptor @5 04 @6 «D1» Dopamine receptor`
C03	`04`	`X`	`SPA`	`@0 Receptor dopaminérgico D1 @5 04`
C03	`05`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 05`
C03	`05`	`X`	`ENG`	`@0 Dopamine agonist @5 05`
C03	`05`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 05`
C03	`06`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 06`
C03	`06`	`X`	`ENG`	`@0 Dopamine receptor @5 06`
C03	`06`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 06`
C03	`07`	`X`	`FRE`	`@0 Comportement @5 07`
C03	`07`	`X`	`ENG`	`@0 Behavior @5 07`
C03	`07`	`X`	`SPA`	`@0 Conducta @5 07`
C03	`08`	`X`	`FRE`	`@0 Parkinson maladie @5 10`
C03	`08`	`X`	`ENG`	`@0 Parkinson disease @5 10`
C03	`08`	`X`	`SPA`	`@0 Parkinson enfermedad @5 10`
C03	`09`	`X`	`FRE`	`@0 Apomorphine @2 NK @2 FR @5 11`
C03	`10`	`X`	`FRE`	`@0 Lévodopa @5 13`
C03	`10`	`X`	`ENG`	`@0 Levodopa @5 13`
C03	`10`	`X`	`SPA`	`@0 Levodopa @5 13`
C03	`11`	`X`	`FRE`	`@0 Association médicamenteuse @5 14`
C03	`11`	`X`	`ENG`	`@0 Drug combination @5 14`
C03	`11`	`X`	`SPA`	`@0 Asociación medicamentosa @5 14`
C03	`12`	`X`	`FRE`	`@0 Animal @5 16`
C03	`12`	`X`	`ENG`	`@0 Animal @5 16`
C03	`12`	`X`	`SPA`	`@0 Animal @5 16`
C03	`13`	`X`	`FRE`	`@0 Singe @5 17`
C03	`13`	`X`	`ENG`	`@0 Monkey @5 17`
C03	`13`	`X`	`SPA`	`@0 Mono @5 17`
C03	`14`	`X`	`FRE`	`@0 Long terme @5 18`
C03	`14`	`X`	`ENG`	`@0 Long term @5 18`
C03	`14`	`X`	`SPA`	`@0 Largo plazo @5 18`
C03	`15`	`X`	`FRE`	`@0 Voie orale @5 19`
C03	`15`	`X`	`ENG`	`@0 Oral administration @5 19`
C03	`15`	`X`	`SPA`	`@0 Vía oral @5 19`
C03	`16`	`X`	`FRE`	`@0 Latence réponse @5 21`
C03	`16`	`X`	`ENG`	`@0 Response latency @5 21`
C03	`16`	`X`	`SPA`	`@0 Latencia respuesta @5 21`
C03	`17`	`X`	`FRE`	`@0 Durée action @5 22`
C03	`17`	`X`	`ENG`	`@0 Duration of action @5 22`
C03	`17`	`X`	`SPA`	`@0 Duración acción @5 22`
C03	`18`	`X`	`FRE`	`@0 Dose répétée @5 23`
C03	`18`	`X`	`ENG`	`@0 Multiple dose @5 23`
C03	`18`	`X`	`SPA`	`@0 Dosis múltiple @5 23`
C03	`19`	`X`	`FRE`	`@0 Activité biologique @5 24`
C03	`19`	`X`	`ENG`	`@0 Biological activity @5 24`
C03	`19`	`X`	`SPA`	`@0 Actividad biológica @5 24`
C03	`20`	`X`	`FRE`	`@0 SCH 23390 @2 FR @4 INC @5 86`
C03	`21`	`X`	`FRE`	`@0 NNC 010112 @2 FR @4 INC @5 87`
C03	`22`	`X`	`FRE`	`@0 Antiparkinsonien`
C03	`22`	`X`	`ENG`	`@0 Antiparkinson agent`
C03	`22`	`X`	`SPA`	`@0 Antiparkinsoniano`
C07	`01`	`X`	`FRE`	`@0 Primates @2 NS`
C07	`01`	`X`	`ENG`	`@0 Primates @2 NS`
C07	`01`	`X`	`SPA`	`@0 Primates @2 NS`
C07	`02`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`02`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`03`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`03`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 61`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 61`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 61`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 62`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 62`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 62`
C07	`06`	`X`	`FRE`	`@0 Encéphale pathologie @5 63`
C07	`06`	`X`	`ENG`	`@0 Cerebral disorder @5 63`
C07	`06`	`X`	`SPA`	`@0 Encéfalo patología @5 63`
C07	`07`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 64`
C07	`07`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 64`
C07	`07`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 64`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 65`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 65`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 65`
N21				`@1 340`

Format Inist (serveur)

NO :	PASCAL 99-0526518 INIST
ET :	Effect of the selective D₁ antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
AU :	DOAN (V. D.); GRONDIN (R.); ABDALLAH HADJ TAHAR; GREGOIRE (L.); BEDARD (P. J.)
AF :	Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University/Québec/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1999; Vol. 22; No. 5; Pp. 281-287; Bibl. 37 ref.
LA :	Anglais
CC :	002B02B06
FD :	Antagoniste dopamine; Antagoniste; Agoniste; Récepteur dopaminergique D1; Stimulant dopaminergique; Récepteur dopaminergique; Comportement; Parkinson maladie; Apomorphine; Lévodopa; Association médicamenteuse; Animal; Singe; Long terme; Voie orale; Latence réponse; Durée action; Dose répétée; Activité biologique; SCH 23390; NNC 010112; Antiparkinsonien
FG :	Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Dopamine antagonist; Antagonist; Agonist; D1 Dopamine receptor; Dopamine agonist; Dopamine receptor; Behavior; Parkinson disease; Levodopa; Drug combination; Animal; Monkey; Long term; Oral administration; Response latency; Duration of action; Multiple dose; Biological activity; Antiparkinson agent
EG :	Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Antagonista dopamina; Antagonista; Agonista; Receptor dopaminérgico D1; Estimulante dopaminérgico; Receptor dopaminérgico; Conducta; Parkinson enfermedad; Levodopa; Asociación medicamentosa; Animal; Mono; Largo plazo; Vía oral; Latencia respuesta; Duración acción; Dosis múltiple; Actividad biológica; Antiparkinsoniano
LO :	INIST-16720.354000087950320060
ID :	99-0526518

Links to Exploration step

Pascal:99-0526518

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</title>
<author><name sortKey="Doan, V D" sort="Doan, V D" uniqKey="Doan V" first="V. D." last="Doan">V. D. Doan</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0526518</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0526518 INIST</idno>
<idno type="RBID">Pascal:99-0526518</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D27</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</title>
<author><name sortKey="Doan, V D" sort="Doan, V D" uniqKey="Doan V" first="V. D." last="Doan">V. D. Doan</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R." last="Grondin">R. Grondin</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abdallah Hadj Tahar" sort="Abdallah Hadj Tahar" uniqKey="Abdallah Hadj Tahar" last="Abdallah Hadj Tahar">ABDALLAH HADJ TAHAR</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L." last="Gregoire">L. Gregoire</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P. J." last="Bedard">P. J. Bedard</name>
<affiliation><inist:fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Clinical neuropharmacology</title>
<title level="j" type="abbreviated">Clin. neuropharmacol.</title>
<idno type="ISSN">0362-5664</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Animal</term>
<term>Antagonist</term>
<term>Antiparkinson agent</term>
<term>Behavior</term>
<term>Biological activity</term>
<term>D1 Dopamine receptor</term>
<term>Dopamine agonist</term>
<term>Dopamine antagonist</term>
<term>Dopamine receptor</term>
<term>Drug combination</term>
<term>Duration of action</term>
<term>Levodopa</term>
<term>Long term</term>
<term>Monkey</term>
<term>Multiple dose</term>
<term>Oral administration</term>
<term>Parkinson disease</term>
<term>Response latency</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste dopamine</term>
<term>Antagoniste</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D1</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique</term>
<term>Comportement</term>
<term>Parkinson maladie</term>
<term>Apomorphine</term>
<term>Lévodopa</term>
<term>Association médicamenteuse</term>
<term>Animal</term>
<term>Singe</term>
<term>Long terme</term>
<term>Voie orale</term>
<term>Latence réponse</term>
<term>Durée action</term>
<term>Dose répétée</term>
<term>Activité biologique</term>
<term>SCH 23390</term>
<term>NNC 010112</term>
<term>Antiparkinsonien</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0362-5664</s0>
</fA01>
<fA02 i1="01"><s0>CLNEDB</s0>
</fA02>
<fA03 i2="1"><s0>Clin. neuropharmacol.</s0>
</fA03>
<fA05><s2>22</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>DOAN (V. D.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GRONDIN (R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>ABDALLAH HADJ TAHAR</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>GREGOIRE (L.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BEDARD (P. J.)</s1>
</fA11>
<fA14 i1="01"><s1>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University</s1>
<s2>Québec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>281-287</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>16720</s2>
<s5>354000087950320060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0526518</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Clinical neuropharmacology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Antagoniste</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Antagonist</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Antagonista</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique D1</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>D1 Dopamine receptor</s0>
<s5>04</s5>
<s6>«D1» Dopamine receptor</s6>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico D1</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Comportement</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Behavior</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Conducta</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Apomorphine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Animal</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Singe</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Monkey</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Mono</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Long terme</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Long term</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Voie orale</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Oral administration</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Vía oral</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Latence réponse</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Response latency</s0>
<s5>21</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Latencia respuesta</s0>
<s5>21</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Durée action</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Duration of action</s0>
<s5>22</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Duración acción</s0>
<s5>22</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Dose répétée</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Multiple dose</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Dosis múltiple</s0>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Activité biologique</s0>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Biological activity</s0>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Actividad biológica</s0>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>SCH 23390</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="21" i2="X" l="FRE"><s0>NNC 010112</s0>
<s2>FR</s2>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="22" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
</fC03>
<fC03 i1="22" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
</fC03>
<fC03 i1="22" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Primates</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>61</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>61</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>62</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>62</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>63</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>63</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>64</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>65</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>65</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>65</s5>
</fC07>
<fN21><s1>340</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0526518 INIST</NO>
<ET>Effect of the selective D<sub>1</sub>
 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys</ET>
<AU>DOAN (V. D.); GRONDIN (R.); ABDALLAH HADJ TAHAR; GREGOIRE (L.); BEDARD (P. J.)</AU>
<AF>Neurobiology Research Center, Enfant-Jesus Hospital and Faculty of Medicine, Laval University/Québec/Canada (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Clinical neuropharmacology; ISSN 0362-5664; Coden CLNEDB; Etats-Unis; Da. 1999; Vol. 22; No. 5; Pp. 281-287; Bibl. 37 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Antagoniste dopamine; Antagoniste; Agoniste; Récepteur dopaminergique D1; Stimulant dopaminergique; Récepteur dopaminergique; Comportement; Parkinson maladie; Apomorphine; Lévodopa; Association médicamenteuse; Animal; Singe; Long terme; Voie orale; Latence réponse; Durée action; Dose répétée; Activité biologique; SCH 23390; NNC 010112; Antiparkinsonien</FD>
<FG>Primates; Mammalia; Vertebrata; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Dopamine antagonist; Antagonist; Agonist; D1 Dopamine receptor; Dopamine agonist; Dopamine receptor; Behavior; Parkinson disease; Levodopa; Drug combination; Animal; Monkey; Long term; Oral administration; Response latency; Duration of action; Multiple dose; Biological activity; Antiparkinson agent</ED>
<EG>Primates; Mammalia; Vertebrata; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Antagonista dopamina; Antagonista; Agonista; Receptor dopaminérgico D1; Estimulante dopaminérgico; Receptor dopaminérgico; Conducta; Parkinson enfermedad; Levodopa; Asociación medicamentosa; Animal; Mono; Largo plazo; Vía oral; Latencia respuesta; Duración acción; Dosis múltiple; Actividad biológica; Antiparkinsoniano</SD>
<LO>INIST-16720.354000087950320060</LO>
<ID>99-0526518</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D27 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D27 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:99-0526518
   |texte=   Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Effect of the selective D1 antagonists SCH 23390 and NNC 01-0112 on the delay, duration, and improvement of behavioral responses to dopaminergic agents in MPTP-treated monkeys

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri